Selling Biopharma to Stabilize GE's Balance Sheet

Culp explains selling the life sciences unit to raise $21 billion and how that cash averted catastrophe ahead of the pandemic.

Play episode from 17:37

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!